Peptide blends explained

What a peptide blend is

Online sellers increasingly sell two or more peptides mixed in one vial. Some of the most common:

• BPC-157 with TB-500
• "GLOW": BPC-157, GHK-Cu and TB-500
• "KLOW": the same three plus KPV
• CJC-1295 with ipamorelin
• Retatrutide with cagrilintide
• Cagrilintide with semaglutide

Names like GLOW and KLOW are marketing labels made up by sellers. They are not medical or scientific terms.

What the evidence says about combinations

Each ingredient has its own evidence, which is often thin. But a mix is a new product. Whether two peptides are safe and useful together has to be tested together.

Blend	Human trials of the combination
CagriSema (cagrilintide plus semaglutide)	Yes. Large Phase 3 trials of Novo Nordisk's own product.[1][2]
BPC-157 with TB-500	None found
GLOW and KLOW	None found
CJC-1295 with ipamorelin	None found
Retatrutide with cagrilintide	None found

The individual ingredients are not on solid ground either. FDA lists limited or no human safety data for BPC-157, TB-500, injectable GHK-Cu and KPV, has raised immune reaction concerns for several of them, and notes serious side effects reported with CJC-1295, including a fast heart rate.^[3] Retatrutide is not part of any approved drug and federal law bars it from compounding.^[4] Cagrilintide and retatrutide sold online have drawn FDA warning letters as unapproved drugs.^[5] Semaglutide is approved, but only as prescription products.^[6]

How CagriSema is different

CagriSema shows what testing a combination properly looks like. In the REDEFINE 1 trial, more than 3,000 adults with obesity or overweight were randomly assigned to the combination, to cagrilintide alone, to semaglutide alone, or to placebo for 68 weeks. Average weight loss was about 20 percent with the combination versus 3 percent with placebo. Stomach and gut side effects were common, affecting 80 percent of people on the combination versus 40 percent on placebo.^[1]

Testing each part alone next to the combination is what lets researchers say whether the mix adds anything. Novo Nordisk announced in December 2025 that it had filed for FDA approval.^[2] A seller's vial labeled cagrilintide and semaglutide is not CagriSema. It was not made or tested in those trials. FDA has warned a seller that promoted that exact pairing for weight loss.^[5]

Mixing hides who caused a problem

When FDA reviewed reports of side effects linked to BPC-157, one involved a product that also contained TB-500. FDA said that with two peptides present, it could not judge whether BPC-157 was related to the reported problems.^[7] With a blend, you and your doctor face the same problem.

Mixing changes stability

Peptides break down in liquid in several ways, including splitting, reacting with oxygen and clumping together. How fast that happens depends on acidity, temperature, concentration and every other ingredient in the solution. Metal ions, for example, can speed up oxidation of some amino acids.^[8] That may matter in blends with GHK-Cu, which carries copper. A vial built for one peptide is not automatically stable for three. We found no published stability data for these seller blends.

Mixing makes testing harder

Checking one peptide well already takes several methods, including HPLC for purity, mass spectrometry for identity and separate tests for content.^[9] In a blend, the lab has to separate and measure each peptide and each one's impurities without them overlapping. A single "99 percent pure" number on a blend does not say which peptide it refers to. FDA found that even single peptide CoAs online usually show only purity.^[7]

Undisclosed ingredients are a red flag

Some blends are sold as a "proprietary" or "signature" formula without listing every ingredient and amount. If you cannot see exactly what is in the vial, you cannot check it against anything. FDA warns that counterfeit weight loss drugs may contain the wrong ingredients, too much or too little drug, or none at all.^[4] Treat any blend without a full ingredient list, and a CoA for each ingredient, as a reason to walk away.

A note for athletes

The World Anti-Doping Agency bans BPC-157 at all times as an unapproved substance. It also bans TB-500 and growth hormone releasing peptides such as ipamorelin.^[10] One prohibited ingredient makes the whole blend prohibited.

Bottom line

Apart from CagriSema, these blends have essentially no published human studies as combinations. Mixing adds stability and testing problems on top of ingredients that are already unproven.

Sources

1. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2502081
2. Novo Nordisk. Company announcement of a New Drug Application submission to the U.S. FDA for CagriSema. December 18, 2025. Novo Nordisk announcement
3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA list
4. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated October 1, 2026. FDA safety page
5. U.S. Food and Drug Administration. Warning Letter to Summit Research Peptides, MARCS-CMS 695607. December 10, 2024. FDA warning letter
6. U.S. Food and Drug Administration. Warning Letter to USApeptide.com, MARCS-CMS 696885. February 26, 2025. FDA warning letter
7. U.S. Food and Drug Administration. FDA Evaluation of BPC-157 Related Bulk Drug Substances. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. FDA briefing document (PDF)
8. Nugrahadi PP, Hinrichs WLJ, Frijlink HW, Schöneich C, Avanti C. Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics. 2023;15(3):935. doi:10.3390/pharmaceutics15030935
9. McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023;40:1317-1328. doi:10.1007/s11095-023-03493-1
10. World Anti-Doping Agency. The Prohibited List (2026 List in force). WADA page